Spinnovation Transfers its Entire Operation to Pivot Park
News Jan 13, 2014
Spinnovation Analytical BV has today announced the transfer of its entire operations to Pivot Park in Oss, the Netherlands. Since 2013, Spinnovation has collaborated with Pivot Park by supplying analytical services to life science companies based on the site. The new location has enabled Spinnovation to double the size of its facilities, to support the growth of its business. Furthermore, this new location will facilitate the development of GMP compliant services and expand Spinnovation’s analytical capabilities.
Spinnovation Analytical BV provides a range of analytical services for the pharmaceutical and biopharmaceutical industries. Having first opened laboratories and offices in Pivot Park in February 2013, Spinnovation has supported the park’s initiative for open access and exchange of knowledge by providing tenants at the site with access to advanced analytical technologies. Spinnovation offers innovative NMR-based testing and profiling methods, in addition to ESI-TOF MS, HPLCs, LC-SPE and ICP-OES applications. Spinnovation Biologics also offers unique services for biologics upstream development, including Spedia-NMR™ for spent cell media analysis and Spedia-Predict™ for troubleshooting bioprocessing issues.
Jules de Vet, interim Director of Pivot Park, commented, “Since their move here last year, Spinnovation has proved a valuable partner for Pivot Park and its tenants. We are delighted to hear that Spinnovation will be transferring their full operation and expanding their presence at Pivot Park and will be able to deliver even more analytical services to our tenants.”
Frederic Girard, CEO of Spinnovation Analytical, said, “We are very pleased with the success of our partnership with Pivot Park and we are thrilled to expand our presence here. With our larger facility, we can better cope with the growth of our services for our customers across Europe and the United States, while securing access to industry leading analytical applications for park tenants. Transferring our facility will enable us to capitalize on our success in 2013, work towards GMP-compliant assays and testing capabilities and continue to develop and grow our innovative analytical services during 2014 and beyond.”
Researchers have developed an artificial enzymatic pathway for synthesizing isoprenoids, or terpenes, in E. coli. This shorter, more efficient, cost-effective and customizable pathway transforms E. coli into a factory that can produce terpenes for use in everything from cancer drugs to biofuels.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019